杭州品茶工作室

　　From May 21st to June 13th, 19 enterprises including () (603392.SH), () (605337.SH) and () (300485.SZ) successively indicated on the investor platform that there was no synthetic biology related business or application (see Figure 1) for the time being, mainly because there was no technical reserve or none.

　　In sharp contrast to the cautious attitude of these enterprises towards synthetic biology, in the last two months, the concept stocks labeled with synthetic biology in the secondary market have soared.

　　The data shows that in the past 60 days, nearly 40% of the 27 synthetic biology concept stocks have risen. Among them, () (301301.SZ), () (603739.SH) and () (002773.SZ) led the way, with increases of 39%, 29% and 29% respectively. Seven stocks rose more than 5% (the opening price on June 18th).

　　This large group increase in share prices is considered to be driven by favorable policies. At the end of April, at the annual meeting of Zhongguancun Forum, Tan Tianwei, an academician of China Academy of Engineering, emphasized that bio-manufacturing is a very important new track and new format for new quality productivity. Led by the National Development and Reform Commission, the Ministry of Industry and Information Technology, the Ministry of Science and Technology and other national ministries and commissions are jointly developing a national action plan for biotechnology and bio-manufacturing, which is expected to be introduced in the near future.

　　Synthetic biology is not a new concept, it was first born in early 2000, and it is considered as the "third life science and technology revolution" after the discovery of DNA double helix structure and the human genome project.

　　To put it simply, the way of synthetic biology is to transform the genes of microorganisms such as bacteria, so that they can produce raw materials needed by human beings in metabolism, such as plastics, food or medicines, which can be applied to medical treatment, environment, health, energy, food, agriculture and other industries. This mode of production is often more environmentally friendly than traditional chemical methods, or it can produce new products that cannot be realized by chemical methods.

　　This is not the first time that synthetic biology has set off a market boom. The last wave of capital influx was in 2021, when there were 458 financing events in the field of synthetic biology in China, and the financing amount reached 113.6 billion yuan, all of which were the highest level since 2019.

　　At that time, Ginkgo Bioworks and Zymergen of the United States successively landed on NASDAQ. Both companies are platform-based enterprises that provide synthetic biology technology, and their listing also drives domestic hot money to flood into synthetic biology start-ups.

　　However, in less than three years, the three giants of American synthetic biology were almost wiped out, and the related investment and financing also fell to freezing point.

　　Amyris, the world’s first synthetic biology listed company, was once famous for producing artemisinin by using synthetic biology technology. However, after the development of bio-fuel products failed, it expanded its cosmetics raw materials and other businesses on a large scale, and its debts snowballed until the bubble burst, and it went bankrupt and liquidated in 2023.

　　Also in 2023, Zymergen went bankrupt. At first, it only focused on the development of strains. Later, it turned to the development of products, and chose an optical film Hyaline, which can be used in electronic products such as folding screens. However, mass production failed, and the entire synthetic biology sector in the United States plummeted. Zymergen was acquired by Ginkgo Bioworks after bankruptcy.

　　However, the surviving Ginkgo Bioworks is hard to say success. They insisted on making technology instead of products, and their market value fell by 92%, and their stock price was as low as 0.99 US dollars. In May 2024, they received a warning of delisting.

　　Industry martyrs have proved with painful reality that the concept of synthetic biology is very popular, but it is difficult to do business in this crater-selecting products, mass production, and developing business models. One wrong step may lose the game.

　　Who is the real synthetic biology enterprise?

　　Many practitioners said that enterprises in China are concentrated in the downstream field of synthetic biology, product-oriented, and there are few platform-based enterprises that provide technology.

　　A reference perspective is that, as an instrument supplier, synthetic biology is one of the fastest growing sectors of Agilent’s business in China, and its customer business focuses on bulk chemical raw materials, food additives, pharmaceutical and cosmetic raw materials.

　　Figure 2 shows the top ten companies in the synthetic biology concept stocks, and they are also the players that the market thinks are more promising, including Huaheng Bio (688639.SH), Huaxi Bio (688363.SH), Tebao Bio (688278.SH), Kaisai Bio (688065.SH) and () (600298.

　　These enterprises entered the field of bio-manufacturing earlier and firmly occupied the leading position in the subdivision track.

　　Huaheng Bio’s global market share of alanine exceeds 50%; Huaxi Bio is the largest supplier of sodium hyaluronate in the world, accounting for 44%. The long-chain dibasic acid produced by Kaisai Bio-accounts for 90% of the global market share.

　　Companies with stock prices in the top ten generally have two characteristics: one is mature products, and the other is rich experience in mass production.

　　A technician who has been engaged in synthetic biology research for many years said that when a company has made clear the synthetic biology methods used, it still needs to solve the problem of mass production. This is called "crossing the Death Valley from lab (laboratory) to fab (factory)" in the industry, and it will be scaled up to the industrial level after small-scale and pilot-scale tests.

　　In the research and development stage, the screening of strains is the key, and the characteristics of chassis cells should be studied for many years. In industrial scale-up, it is necessary to control fermentation temperature, time, dissolved oxygen and miscellaneous bacteria pollution more precisely, and the difficulty coefficient increases exponentially. After the problems appear, we should go back to the most basic strain optimization, reconstruct the metabolic pathway, and repeat it many times to achieve a breakthrough in strain tolerance and yield.

　　Gong Mo, general manager of Lingdao Capital, vividly explained the differences in each stage. It takes several years or even more to do basic research in the laboratory, and it is enough for a doctor to graduate after entering the pilot stage, which requires at least five years and tens of millions of dollars. It’s not a sudden idea that can be realized immediately. She said that investors are more optimistic about the team with long-term experience in basic research and industrialization. This kind of industrialization experience is best accumulated in downstream separation, extraction and purification.

　　Different industries have different definitions of "mass production". For example, the overall demand for cosmetic raw materials is small and the unit value is high. Therefore, the pilot scale is kilograms per year and the mass production is tons. For the chemical and material industries with large demand and low unit value, the pilot scale is at least 1,000 tons, and the mass production is calculated based on an annual output of one million tons.

　　The ability of mass production is so critical that after the concept of synthetic biology broke out in 2021, many enterprises raised funds mainly for building new industrial lines and expanding production capacity.

　　See the direction of the enterprise from the location of the new factory. In coastal areas such as Yancheng, Tianjin and other places, factories are mainly built by enterprises with small mass production scale and products going to sea. There is sufficient wind power in the local area, which is convenient for export and sales near ports. Enterprises with larger production capacity will directly choose places such as Xinjiang and Inner Mongolia where raw materials such as electricity, energy and corn are cheaper.

　　Among the concept stocks, Huaheng Bio has completed the expansion of Qinhuangdao and Bayannaoer bases, with the current production capacity of 100,000 tons and 50,000 tons. In addition, it has built a new material production base with a production capacity of 100,000 tons in Chifeng, Inner Mongolia.

　　Kaisai Bio’s 100,000-ton bio-based polyamide production line in Wusu production base in Xinjiang has been put into production. Huaxi Bio’s Tianjin plant has been put into production, and 64 pilot production lines are planned to be built. The overall production capacity of bioactive materials is planned to reach 1,000 tons.

　　Among the synthetic biology concept stocks, most enterprises are still in the initial stage of layout.

　　For example, Angel Yeast’s subsidiary Weiqi Enterprise, with an annual output of 10,000 tons, is under construction, and the first phase is planned to be put into production in 2025.

　　Azure Bio, whose daily limit has been raised for many times, shows that the enterprise has only set up a synthetic biology technology innovation laboratory, which is still in the research and development stage of the early strain laboratory and does not have the conditions for industrialization.

　　Product homogeneity is serious.

　　Synthetic biology is still in the early stage, because people’s understanding of the biological field is less than 10%, which brings a common phenomenon in synthetic biology enterprises-product homogenization.

　　The involution of cosmetic raw material enterprises is particularly serious.

　　There are more than 40 synthetic biology enterprises engaged in the development of cosmetic raw materials in China. Many start-ups and listed companies have plunged into squalene, ergothionine, icodoline and other popular raw materials with moisturizing and antioxidant effects.

　　At present, the listed companies with mass production capacity in China are mainly Huaxi Bio and Chuanning Bio. Ultra-pure ergothionine produced by Huaxi Bio-technology has a purity of over 99%. At the end of May, Chuanning Bio announced that some synthetic biological products have entered the stage of small-scale and pilot-scale, including squalene, ergothionine, and icodoline.

　　The aforementioned technicians believe that when making the same product, the volume concentration, volume purity, volume impurities, etc. really make the quality of raw materials better, and also knock down the original inflated price. For example, the price of ergothione was 200,000 yuan/kg a few years ago, and now it is only tens of thousands of yuan/kg.

　　However, cosmetics raw materials are a relatively small market, and the enterprises that enter the market first will have advantages, and most of the enterprises that enter the market later can only fight price wars, or suffer heavy losses because of drastic price changes.

　　In February this year, Sinochem, one of the earliest enterprises that made ergothionine, declared bankruptcy. The enterprise was founded in 2016, when there were almost no enterprises that produced ergothionine in China.

　　According to public information, Zhongke Nuozhi and Tianjin Institute of Industrial Biology, China Academy of Sciences agreed to realize the industrialization of ergothionine within 4 years after it passed the verification level of 75L fermentor, which means that it should be produced in at least 1000L fermentor.

　　However, in 2020, which was supposed to be the test result, Zhongke Nuozhi suffered a triple blow from inside and outside: it failed to mass produce, the price of ergothionine began to decrease, and it was deeply involved in various judicial cases and disputes.

　　In this year, the number of judicial cases involved in Kono Knowledge exceeded 60, which was the highest in the past years, including private lending disputes, patent transfer contract disputes, service contract disputes, labor disputes and so on. A year later, the court ruled that Kono paid R&D expenses and breach of contract fees, and transferred the development patent back to Tianjin Institute of Technology.

　　The bankruptcy of Zhongke Nuozhi shows the other side behind the scenery of synthetic biology track. The market turmoil and the ability of enterprises to land can directly determine life and death.

　　In addition, for some products, even if the price is lowered by the method of synthetic biology, it can not stimulate demand, and it is a waste of production capacity to be involved, so the forward-looking selection of products by enterprises is particularly critical.

　　For example, Glutathione, a raw material drug with the functions of protecting liver and whitening, is quoted at a price of about 800 yuan/kg-900 yuan/kg by using traditional yeast, and () (300233.SZ) occupies about 90% of the market share in China. Glutathione produced by synthetic biological process is quoted at about 600 yuan/kg-700 yuan/kg, but Jincheng Medicine still occupies 90% of the market.

　　This is because, on the one hand, the price drop is relatively low, which has not impacted the market; on the other hand, the change of pharmaceutical raw materials needs to be reapplied for approval, and the process is very complicated. Safety and stability are more critical factors than cost.

　　To sum up, there are two reasons for the homogenization of involution products in synthetic biology enterprises:

　　First, the raw materials of cosmetics are mainly small molecular compounds and monomer materials. At present, both the research on the characteristics of chassis cells and the environmental control of mass production are very mature. If the price in the market is high, more enterprises will flock to do it.

　　Second, China’s current policies are relatively stricter in food, medicine, agriculture and other fields. For example, the longest approval period for biological pesticides can reach 8-10 years.

　　Many practitioners said that the standards committee related to synthetic biology in China is gradually being established, and the access and process of approval will be improved in the future. However, what determines the profitability of enterprises at present is the ability to expand diversified product lines and find materials with a wider range of applications through long-term research and development.

　　Dong Lei, dean of the School of Life Sciences of Nanjing University, told the Economic Observer that the focus of synthetic biology around the world is mainly on the synthesis of small molecules, but not on macromolecular materials, because the synthetic steps involved are more complicated and difficult.

　　New materials, new business

　　Many enterprises that started earlier are also producing macromolecular materials based on synthetic biology. The leading ones are polymers in the chemical industry, such as PHA (polyhydroxy fatty acid ester, note: a kind of bio-polyester, which has degradable characteristics) and polyamide materials (nylon).

　　In the past, chemical companies such as Kaisai Bio and Huaheng Bio mainly sold small molecular monomer materials such as dibasic acid and alanine. They made them by biological method instead of chemical method, which reduced the cost and seized a larger market share.

　　It is difficult to reduce the short-term cost of macromolecular new materials, and the market has not been widely accepted, so enterprises are also exploring new business models. The most representative is that raw material enterprises directly go off to build brands or jointly manufacture products.

　　Many synthetic biology enterprises have flocked to PHA racetrack. This material has good biocompatibility, biodegradability and thermal processability, and can be applied to food packaging, fiber fabrics, agricultural mulching films, drug delivery and medical materials.

　　Blue Crystal Microbes is one of the start-ups with the most financing in synthetic biology. Since its establishment in 2016, it has completed 10 rounds of financing and disclosed that the total financing amount exceeds 2 billion yuan.

　　Li Teng, co-founder and president of Blue Crystal Microbes, told the Economic Observer that they have been doing PHA since its establishment, providing only technical services and not making products. It is difficult for start-ups to survive. If they only make popular products at the moment, they will be eliminated in a few years.

　　Li Teng said that at first, their definition of PHA was a fine chemical, but now it has changed into a bulk chemical. He explained that this adjustment is market demand-oriented. Unlike other enterprises, blue crystal microorganisms hope to use the same PHA to meet different needs. Blue crystal PHA is made because it has the greatest potential for cost reduction, the highest product adaptability, and the corresponding technical difficulty is higher. Stability and quality are the most priority factors, followed by cost.

　　The direct profit of Blue Crystal Microbes is to cooperate with brands and manufacturers to jointly develop PHA products, including disposable products, soft and hard packaging, textile fibers and so on. The annual production capacity of blue crystal PHA is 5000 tons, and the output of downstream products is 5000 tons, which belongs to the first echelon among PHA manufacturing enterprises at home and abroad.

　　In addition, cyanobacteria also develop in the middle and upper reaches, providing platforms and technologies to incubate small enterprises.

　　Li Teng said that in the past, they only produced products, but now it may be a turning point. They have observed that more and more small enterprises are also entering. However, the capabilities provided by incubators and biomedical sharing platforms on the market are different from the actual needs.

　　For example, most synthetic biology laboratories usually emphasize the automation of Qualcomm quantity, but most strain development processes do not need Qualcomm quantity, which is different from drug research and development, which needs to screen many different molecules. Therefore, Blue Crystal is helping small enterprises to improve efficiency through its own experience, such as technical services and laboratory sharing.

　　As the leading supplier of long-chain dibasic acids in the world, Kaisai Bio is also the first enterprise in the world to realize bio-based polyamide (note: dibasic acids and diamines are important monomer raw materials of polyamide). The pilot test of this material was completed in 2014, and the production line with an annual output of 100,000 tons was completed and put into production in 2021.

　　Although the production capacity has increased significantly, the actual sales volume has increased less.

　　According to the prospectus, from 2016 to 2021, the sales volume of bio-based polyamide increased from 0.5 million tons to 0.7 million tons, and the ratio of production to sales was always around 50%. In contrast, the sales volume of long-chain diacid, the ace product, increased from 25,000 tons to 61,000 tons.

　　According to Kaiser Bio, bio-based polyamide is a brand-new material, its price is higher than that of nylon made by chemical method, and its application ability is still being explored.

　　Bio-new materials made of new polymer materials need to provide a whole set of solutions, tell customers how to process and produce, jointly research and develop with downstream, and even assist customers in carbon footprint, equipment and technology, so as to make the market accept them faster. In this regard, Kaisai Bio has established an interdisciplinary R&D center, which has made remarkable progress in the textile field, engineering materials and composite materials.

　　In addition, Kaisai Bio has established its own fiber brand TERRYL to provide fiber solutions for the textile field.

　　For example, we cooperated with Bosideng’s brand Samet to build school uniforms, and cooperated with close-fitting clothing brands such as Shushu and Ubras to develop underwear, sportswear, yoga clothes and other kinds of clothing. At the same time, we replaced the consumables such as work clothes, helmets and carpets in the internal production base with new materials.

　　Liu Xiucai, chairman of Kaisai Bio, once publicly stated: "We can’t make the business model of synthetic biology too early." In the future, there may be a model similar to the pharmaceutical industry. A startup or research institution has made an efficient and valuable metabolic pathway, but it does not do follow-up research and development, and packages the results and sells them to mature enterprises in the industry to complete it.

　　Cctv newsOn December 5, the National Health and Wellness Commission held a press conference to introduce the measures to deepen the implementation of grassroots health care and convenience services. Zhu Hongming, deputy director of the Grassroots Department of the National Health and Wellness Commission and a first-class inspector, said at the meeting that since the deepening of medical reform in 2009, National Health Commission has continuously promoted the equalization of basic public health services, and grassroots medical and health institutions have undertaken a large number of basic public health services, especially the health management of patients with chronic diseases, and have established relatively stable contacts with urban and rural residents. Many urban and rural residents have already felt this service. In promoting the management of chronic diseases, there are mainly the following measures:

　　First, in the grassroots convenience measures, we will promote the full implementation of long-term prescription services for chronic diseases such as hypertension and diabetes in community health service centers and township hospitals, and gradually expand the coverage of chronic diseases; Provide exercise and diet prescriptions or suggestions for patients with chronic diseases such as diabetes, hyperlipidemia and hypertension.

　　The second is to organize the compilation of the National Guidelines for the Prevention and Control of Hypertension and the National Guidelines for the Prevention and Control of Diabetes, so as to guide local primary medical and health institutions to provide health management services for patients with chronic diseases.

　　The third is to actively promote the training of "medical prevention and management" integrated talents and establish a medical prevention and control integration mechanism. Relying on the contract service of family doctors, we will promote the combination of prevention and medical care, do a good job in health follow-up of key populations, and carry out multi-disease co-management services for patients with chronic diseases such as hypertension and type 2 diabetes, mainly through the integration of medical care and prevention.

　　Fourth, relying on the construction of county medical community, promote the establishment of division of labor and cooperation and two-way referral mechanism between primary medical and health institutions and superior medical institutions, and extend the services of superior hospitals to the grassroots. For patients with chronic diseases with stable conditions, health management services are provided by grass-roots institutions in accordance with norms and guidelines. There are some good explorations and practices in this regard in various places, for example, Tianjin promotes the construction of grass-roots chronic disease management centers, and provides residents with online and offline integrated all-round and full-cycle health services through intelligent auxiliary diagnosis, convenient chronic disease assessment, customized treatment programs and personalized health management. Relying on the construction of county medical associations and urban medical associations, Zhejiang Province has realized that the general diagnosis, treatment and daily management of "two chronic diseases" are mainly based on grass-roots medical and health institutions, realizing linkage from top to bottom and smoothing referral channels.

　　The National Health and Wellness Committee held a press conference on the 10th to introduce the prevention and treatment of respiratory diseases in winter.

　　It is still recommended to vaccinate against influenza if symptoms are not diagnosed and self-healing.

　　Fever, cough, runny nose … After these flu-like symptoms appear, if you don’t go to the hospital to be diagnosed with the flu, do you still need to get the flu vaccine after recovery? When is the vaccination? Xia Gang, director of the Department of Health and Immunity of the National CDC, responded to the suggestion that this situation should still be vaccinated against influenza.

　　Xia Gang explained that there are two main reasons. First, the symptoms of respiratory infection are not specific, and many pathogenic infections may have flu-like symptoms such as fever and headache. However, these symptoms are not necessarily caused by influenza virus, but also by other pathogens, the most common of which is the common cold.

　　Second, there are many types and subtypes of influenza virus that can cause epidemic. After being infected with a certain type or subtype, you may be at risk of being infected with other types or subtypes. For example, if you have been infected with influenza A, you may still be infected with influenza B. The influenza vaccine is a multivalent vaccine covering many different types and subtypes, that is, the commonly used trivalent and tetravalent vaccines. If you are infected with a certain type of influenza and vaccinated with influenza vaccine containing other types of influenza components, you can still play the role of vaccine in preventing this type of influenza.

　　In addition, in the same epidemic season, there are usually different types and subtypes of influenza viruses co-prevalent. At present, the main subtype is influenza A (H3N2), followed by influenza B.. In the past, in the same epidemic season, the dominant strains were gradually transformed from one type to another.

　　Xia Gang stressed that even if there are flu symptoms recently, it is recommended to get flu vaccine as soon as possible after recovery.

　　The overall amount of diagnosis and treatment of children’s respiratory diseases in medical institutions above the second level in China showed a downward trend.

　　Mi Feng, spokesperson of the National Health and Wellness Commission, said that in view of the current high incidence of respiratory diseases, especially children’s respiratory diseases, the National Health and Wellness Commission, state administration of traditional chinese medicine and the National Bureau of Disease Control and Prevention have continuously strengthened monitoring and judgment, dispatched the supply and diagnosis of medical resources in various places, guided the overall deployment of medical resources within and between medical institutions, increased relevant consulting rooms and treatment areas according to the number of patients, and expanded ward resources. Guide secondary hospitals, maternal and child health hospitals, traditional Chinese medicine hospitals, and primary medical and health institutions to "open as much as possible", extend the consultation time, optimize the in-hospital diagnosis and treatment process, improve service efficiency, and effectively protect the needs of pediatric diagnosis and treatment.

　　Mi Feng introduced that at present, the overall amount of diagnosis and treatment of children’s respiratory diseases in medical institutions above the second level in China has shown a downward trend, and the increase in pediatric diagnosis and treatment in some large children’s specialist hospitals and general hospitals has been alleviated to some extent.

　　Judging from the overall situation of fever clinics and emergency departments, the number of patients with respiratory diseases in China has been relatively stable in recent days, especially in primary medical institutions. The overall normal medical services in the country have not been affected.

　　Mi Feng stressed that it is necessary to give full play to the role of medical associations, medical associations, medical groups and Internet medical care, establish a mechanism for collaboration between general hospitals and primary medical institutions, expert sinking and patient referral, and divide patients into different levels to facilitate patients to choose medical treatment reasonably.

　　It is necessary to give full play to the characteristics and advantages of traditional Chinese medicine and combine traditional Chinese and western medicine to improve the prevention and treatment effect.

　　Primary and secondary schools, kindergartens, nursing homes, social welfare homes and other key places and crowded places should implement measures such as ventilation and disinfection, strengthen health science popularization and health monitoring, do personal protection, reduce the spread of diseases and reduce the risk of infection.

　　We should continue to do a good job in vaccination and constantly optimize vaccination services.

1. AionV model: non-operational, with vehicle warranty (4 years or 150,000 kilometers, except wearing parts); The lifetime warranty of Sandian (the first private owner with an annual mileage of ≦ 30,000 kilometers) does not meet any of the above conditions, and the warranty period is 8 years or 150,000 kilometers.

Operation, vehicle warranty (1 year or 150,000 kilometers, except wearing parts); (5 years or 500,000 kilometers); Three-in-one electric drive (3 years or 300,000 kilometers)

2, AionY model: the first owner, the whole vehicle warranty (4 years or 150,000 kilometers, except wearing parts); The lifetime warranty of Sandian (the first private owner with an annual mileage of ≦ 30,000 kilometers) does not meet any of the above conditions, and the warranty period is 8 years or 150,000 kilometers.

Non-first owner, vehicle warranty (4 years or 150,000 kilometers, except wearing parts); Three electricity warranty (8 years or 150,000 kilometers)

3, Plus, Plus, model:

First owner, vehicle warranty (4 years or 150,000 kilometers, except wearing parts); The lifetime warranty of Sandian (the first private owner with an annual mileage of ≦ 30,000 kilometers) does not meet any of the above conditions, and the warranty period is 8 years or 150,000 kilometers.

1905 movie network news Recently, "Uncle Circle 101" led by "Brother Shan Zheng" has occupied the hot search rankings. Of course, our "Sanshui brother" Bo Huang has not been idle, so he chose today to have a "battle for C". On July 5th, Bo Huang, Wang Baoqiang, Yu Hewei and Wang Xun temporarily formed a "Good Play Uncle" group and got together to compete for the gold C position in the upcoming MV.

At the scene, all the fans of the four uncles came to the scene to help, and even more, they played the earthy language of helping, saying, "Over the hills, there will be endless waves", "A thousand troops are easy to get, but treasure is hard to find", "Once it was difficult to cross the sea, but I only loved Yu Hewei all my life" and "My heart is like an island, and I love to grow old". However, it is slightly embarrassing that the fans in Wang Xun did not have time to prepare the aid.

Bo Huang reappeared his high EQ on the spot and explained the meaning of his own words of support. "They don’t sleep, and they can’t reach the height of my hill.".

However, Wang Baoqiang questioned why he appeared here on the spot. "Obviously, I am a post-80 s, closer to the state of LAY." However, Bo Huang immediately replied, "Baoqiang, don’t laugh first, this smile is easy to betray yourself."

In order to run for the C position, four people have shown their unique skills. Yu Hewei first appeared, and performed a drum set with passion, which brought the audience to the climax. After the performance, I immediately took the initiative to do C; Then Wang Baoqiang appeared, bringing a pendant play in Henan. It is worth noting that this lyric was specially customized by Baoqiang for The Island; Later, Wang Xun brought a face-changing performance in Sichuan Opera, which was amazing. After watching the performances of the last two players, Yu Hewei kept saying, "Let’s make C".

Bo Huang always brings something different to everyone. This time, he used blue and white cloth strips as raw materials to design clothes for two spectators at the scene. It turns out that Bo Huang learned this skill after shooting this film.After some contests, Wang Baoqiang was temporarily ahead of the other three with a slight advantage of 18 votes. At this time, LAY was connected to the scene and asked to vote by telephone. Who knows, LAY immediately became "Zhang PD" and evaluated his four brothers, saying that "each has his own merits". Bo Huang on the other end of the phone immediately replied, "I’ll kill you".

However, Bo Huang’s "threat" to LAY goes beyond this, and even more, he made LAY vote for himself on the grounds of "editing scenes". When Bo Huang, the director, offered this big move, several others said that they would retire from the competition, so they could not compete.

Joke aside, the game will go on. Finally, after combining online voting, on-site voting and LAY’s telephone voting, Bo Huang finally made her debut in the C position.

At the same time, the day coincided with the first anniversary of the film The Island. There was also a small commemorative film, and the end of the video was fixed on a tear of director Bo Huang. At the scene, he marveled that he was still crying at that time, and he even vomited himself. "You see how slow I cut." And one side of Yu Hewei, after watching the video, was deeply touched.

It is reported that the film The Island will be released on August 10th.

The progress of China brand cars in recent years is obvious to all, and some excellent achievements have been made in both internal and external design and comprehensive performance. What I bring to you today is that it has many highlights. Let’s take a look at it next.

Let’s take a look at the appearance of the Roewe i5 first. The front of the Roewe i5 is very individual, with a three-piece grille, which looks sporty. Coupled with the exquisite headlights, the overall look is full of coldness. The car is equipped with LED daytime running lights, front fog lights, headlight height adjustment, automatic opening and closing, adaptive distance light, delayed closing and so on. Come to the side of the car, the car body size is 4615MM*1818MM*1489MM, the car uses angular lines, and the car side feels very capable, with large-sized thick-walled tires, the shape is eye-catching. Looking back, the overall shape of the rear of the car echoes the front face, the taillights are very cute, and the unique exhaust pipe creates a good gas field.

Sitting in the car, the overall visual effect of Roewe i5 interior is very distinctive and the visual effect is good. The steering wheel of the car is very simple in shape, equipped with functions such as manual adjustment of the steering wheel up and down, and the grip is full and delicate. Let’s take a look at the central control. The car is decorated with a fashionable touch-control LCD central control screen, which makes the interior design quite layered and conforms to the mainstream aesthetics. The dashboard and seats are equally eye-catching. The dashboard of the car presents a clean and refreshing design style, and the sports atmosphere is relatively in place. The car uses a leather-like seat, and the seat is wrapped in place, which is basically enough for daily use.

Roewe i5 is matched with a wet dual clutch (DCT) gearbox, with a maximum power of 127KW and a maximum torque of 275N.m, with good power performance.

Roewe i5 is equipped with driving mode selection, remote control key, traction control (ASR/TCS, etc.), Bluetooth /WIFI connection, full-speed adaptive cruise and other configurations, which is worthy of praise.

To sum up: the car is a very suitable choice for many families with a moderate size, and the internal space is enough for daily use.

In the automotive market, the launch of new cars always causes a lot of buzz. Not long ago, the 2024 CX-70 was unveiled, and it was heard that its price is expected to start from 300,000. As soon as the news came out, it immediately attracted a lot of interest from fans and consumers, and one of the most interesting questions was, can this car be compared?

Hey, in recent years, the performance in our country has been a bit mediocre. In a lot of joint venture brands, it has long been no longer the leader, and even a little overshadowed. But with the emergence of a new generation of CX-70, Mazda seems to be challenging this situation.

Let’s talk about the exterior design of this car first. Mazda has always been famous for its unique design style, and this CX-70 is no exception. The exterior looks beautiful, full of movement and sporty atmosphere, especially those young people will definitely be attracted. In contrast, although it is also a medium-sized model, its design is a bit old-fashioned and may be a bit outdated.

Then, product strength is also the key to winning. It is said that the CX-70’s interior workmanship and configuration level are quite good, and there may be a large displacement, providing more powerful power. This is definitely a big advantage in the competition.

Finally, let’s talk about the price. I heard that the starting price of this Mazda CX-70 is about 300,000, which is not high compared to Highlander. Coupled with its appearance, interior and power advantages, this price looks quite attractive.

Overall, the appearance of the 2024 Mazda CX-70 provides consumers with a new choice. Although it is not easy to completely beat the mainstream medium-sized like Highlander, Mazda seems to be ready. Its unique design, strong product force and reasonable price positioning all make people look forward to its future. As for whether it can really beat the Highlander? Maybe only time will tell.

From the age of 16 to the present, he has been enjoying success and the brilliance of superstars for most of his life. In addition to Hong Kong and Taiwan actresses, Jackie Chan has had several relationships with Japanese and Korean actresses, which can be described as a long history of love. Let’s take a look at Jackie Chan’s 20 girlfriends.

When Lin Qingxia first entered the entertainment industry, Jackie Chan was in love with the beautiful woman Lin Qingxia, but later did not pursue it because of Qin Xianglin. Later, when Jackie Chan finally fulfilled his long-cherished wish in 1985 when he filmed "Police Story", the two were rumored to have an affair.

In 1979, Jackie Chan had a crush on Mi Xue, expressing his love to Mi Xue with a love letter offensive and a precious sports car of 100,000 yuan, and then the relationship ended. He chased Mi Xue for eight years, and the road was long and hard. Finally, one day he caught up with Mi Xue, and his interest was reduced a lot. He no longer had the strong desire and abnormal excitement he had at the beginning. This is also the fundamental reason why he quickly moved to another love later.

In 1979, Teresa Teng temporarily lived in the United States and met Jackie Chan, who was filming in the United States, and developed a relationship with each other. Jackie Chan said in an interview with "Lu Yu has an appointment" that Lin Fengjiao can get along well with his brothers, and Teresa Teng is "too noble", so in the end he gave up Teresa Teng for his brother and married Lin Fengjiao.

In 1985, Li Zhi and Jackie Chan performed a hot bed scene during the filming of "Double Dragon Club", and the two sides immediately spread an affair, but this affair was the shortest among many actresses.

In 1985, when Jackie Chan and Guan Zhilin were filming the movie "Dragon Brother and Tiger Brother", there was an underground romance, and they were seen eating and watching a play together.

In 1985, Maggie Cheung had an affair with Jackie Chan while filming "Police Story", but the affair also disappeared after the play.

In 1987, it was rumored that Anita Mui committed suicide by drinking medicine for Jackie Chan. Later, the two publicly stated that they were just good friends.

In 1986, after Carina Lau performed Jackie Chan’s production of "The Tricks", the two sides had an affair, and then the woman admitted to dating Tony Leung, and the scandal subsided.

In 1989, Jackie Chan was willing to bid 380,000 Hong Kong dollars to invite Li Jiaxin to perform in a movie. Later, the two appeared together in an international racing car, and the scandal was hot.

　　As one of the leaders of domestic new energy vehicles, BYD can see its products all over the country. As one of the popular SUV models, BYD Tang has always had its own place in people’s discussions. Get the fuel version of BYD Tang test drive model, still has a good sense of freshness, both in appearance and interior, as well as power performance, people feel that BYD has its own unique understanding.

　　The new generation of Tang looks more high-end, not a little higher than the first generation of Tang Yan value.

　　The new model changes the previous slightly stingy design of the middle net and adopts the latest Dragon Face family language design. The whole middle net is much larger, and the middle is filled with lattice small rectangular squares. Headlights look sharper than the old ones.

　　BYD Tang’s appearance is fashionable and dynamic, and Xiaobian has no resistance to this style.

　　The BYD Tang evaluated is a seven-seat car, with Xiaobian’s height of 1.7 meters and a fat figure. When the front seats are adjusted to the lowest level, the head space is about a punch away, which is not bad for Xiaobian. The seats are all wrapped in leather and equipped with electric adjustment. The memory function of the driver’s seat is a practical design. The front seats are also well wrapped, so the legroom is spacious.

　　The simple style and all-black color matching of the interior add a certain sense of mystery and technology to the interior.

　　The highlight of the interior is the 12.8-inch central control panel, which is equivalent to a flat panel placed in the car. It supports functions such as eating chicken and the glory of the king. When you are bored, you can also brush the Tik Tok. It is equipped with the DiLink intelligent network connection system, which should be the most advanced system on the market, supporting rotation, and the most powerful thing is that you can also make video calls. You can put down your mobile phone when you get into this car.

　　In the future, there should be a dual clutch version and a five-seat version of the Tang fuel version. The manufacturer will first launch the 6AT model. After all, the driving texture performance of the 6AT model will indeed be more suitable for driving in urban road conditions. After that, these more energetic reinforcements were mainly to give consumers more choices. BYD Tang Fuel Edition’s ambition is definitely not small, and its strength is indeed not bad. The competition in the medium-sized SUV market will be more intense and exciting. (Zhou Zicheng, Guo Chao)

Solemnly declare:The above content has nothing to do with the position of Securities Star. The purpose of publishing this content by Securities Star is to spread more information. Securities Star is neutral in its opinions and judgments, and does not guarantee the accuracy, authenticity, completeness, effectiveness, timeliness and originality of all or part of this content (including but not limited to words, data and charts). The relevant content does not constitute any investment advice for readers, so operate accordingly at your own risk. The stock market is risky, so you need to be cautious in investing. If you have any objection to this content, or find illegal and bad information, please send an email to jubao@stockstar.com, and we will arrange for verification.